Search
                    Aortic Valve Stenosis Clinical Trials
A listing of 12  Aortic Valve Stenosis  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 12
        
        
    
                There are currently 12 active clinical trials seeking participants for Aortic Valve Stenosis research studies. The states with the highest number of trials for Aortic Valve Stenosis participants are California, New York, Texas and Pennsylvania.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    MRI in Transcatheter Aortic Valve Replacement Patients
                                
            
            
        Recruiting
                            
            
                The hypothesis is that SEV result in superior valvular hemodynamics (more pronounced during exercise) and exercise capacity relative to BEV. Furthermore, the hypothesis is that stress CMR will be able to demonstrate differences in these hemodynamic parameters. CMR will also provide refined assessment of paravalvular leak and its impact on ventricular function and on clinical outcomes.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 105 years
            Trial Updated:
                11/29/2024
            
            Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio         
        
        
            Conditions: Aortic Valve Stenosis
        
            
        
    
                
                                    ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
                                
            
            
        Recruiting
                            
            
                The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                07/09/2025
            
            Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California  +34 locations         
        
        
            Conditions: Aortic Valve Insufficiency, Aortic Valve Stenosis
        
            
        
    
                
                                    PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
                                
            
            
        Recruiting
                            
            
                This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis.
Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.             
        
        
    Gender:
                ALL
            Ages:
                65 years and above
            Trial Updated:
                07/08/2025
            
            Locations: Heart Center LLC, Huntsville, Huntsville, Alabama  +79 locations         
        
        
            Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
        
            
        
    
                
                                    NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study
                                
            
            
        Recruiting
                            
            
                Background:
Some people have a condition in which the wall (septum) that separates the two main pumping chambers of the heart is too thick. This thick septum causes a condition called "left ventricular outflow tract obstruction" (LVOTO), which reduces blood flow out of the heart. LVOTO can cause serious heart disease; symptoms may include shortness of breath, chest pain, heart failure, or death. Researchers want to find better ways to treat LVOTO.
Objective:
To test a new procedure where exce...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 21 years and 99 years
            Trial Updated:
                06/05/2025
            
            Locations: Emory University Hospital, Atlanta, Georgia  +1 locations         
        
        
            Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Septal Hypertrophy, Mitral Valve Disease, Aortic Valve Stenosis
        
            
        
    
                
                                    Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure
                                
            
            
        Recruiting
                            
            
                The clinical and demographic characteristics of patients undergoing transcatheter aortic valve implantation (TAVI) pose unique challenges for coronary computed tomography (CT) imaging, as this patient population is mainly composed of elderly, frail individuals with severe aortic stenosis, multiple comorbidities, high prevalence of heavily calcified coronary artery disease (CAD) and revascularized coronary arteries. Such vulnerable patients could benefit from a more precise assessment and charact...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/04/2025
            
            Locations: Medical University of South Carolina, Charleston, South Carolina  +6 locations         
        
        
            Conditions: Coronary Artery Disease, Aortic Valve Stenosis, Tomography, X-Ray Computed
        
            
        
    
                
                                    Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform
                                
            
            
        Recruiting
                            
            
                This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients w...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/29/2025
            
            Locations: Saint Luke's Health System, Kansas City, Missouri  +5 locations         
        
        
            Conditions: Aortic Valve Stenosis, Mitral Regurgitation
        
            
        
    
                
                                    Effect of Fetal Aortic Valvuloplasty on Outcomes
                                
            
            
        Recruiting
                            
            
                In one of the most severe congenital heart defects, hypoplastic left heart syndrome (HLHS), the left ventricle is underdeveloped and the prognosis is worse than in most other heart defects. The underdevelopment can occur gradually during fetal growth caused by a narrowing of the aortic valve. At some international centers, such fetuses are treated with a balloon dilation of the narrowed valve, but there is no scientifically sound evidence that this treatment is effective.
The aim of this study...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 23 weeks and 31 weeks
            Trial Updated:
                03/18/2025
            
            Locations: Fetal Cardiovascular Program, University of California San Francisco, San Francisco, California  +12 locations         
        
        
            Conditions: Congenital Heart Disease, Aortic Valve Stenosis, Fetal Cardiac Disorder, Hypoplastic Left Heart Syndrome
        
            
        
    
                
                                    Bicuspid Aortic Valve Replacement: Evaluation of Transcatheter Versus Surgery-Pilot Trial
                                
            
            
        Recruiting
                            
            
                The study protocol is a randomized trial of standard of care therapies for severe aortic stenosis (AS) in patients with a bicuspid aortic valve (BAV). Namely, the therapies to which patients will be randomized will be transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), in patients deemed clinically suitable for both following heart team review.
The purpose of this study is to compare the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR)...  Read More             
        
        
    Gender:
                ALL
            Ages:
                50 years and above
            Trial Updated:
                02/05/2025
            
            Locations: Cedars-Sinai Medical Center, Los Angeles, California         
        
        
            Conditions: Aortic Valve Stenosis, Bicuspid Aortic Valve
        
            
        
    
                
                                    Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
                                
            
            
        Recruiting
                            
            
                Data on valve performance following ViV-TAVR has usually been obtained with the use of Doppler-echocardiography. However, some reports have shown significant discordances in the evaluation of mean transvalvular gradient between echocardiography and catheterization, with an overestimation of the real gradient with echo (vs. cath) in most cases. Thus, the incidence of procedural-device failure may be lower than that reported in the ViV-TAVR literature,             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/10/2024
            
            Locations: University of California, San Francisco, California  +6 locations         
        
        
            Conditions: Aortic Valve Stenosis, Aortic Valve Regurgitation, Prosthesis Failure
        
            
        
    
                
                                    Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
                                
            
            
        Recruiting
                            
            
                To assess the efficacy and safety of Intravascular Lithotripsy (IVL) in subjects undergoing transfemoral TAVR in patients with severe iliac disease, prohibitive for transfemoral TAVR in patients with severe symptomatic aortic stenosis, otherwise considered for alternative access TAVR. (e.g. trans-carotid)             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 90 years
            Trial Updated:
                05/08/2023
            
            Locations: Baylor Scott and White Heart Hospital, Plano, Texas         
        
        
            Conditions: Iliac Disease, Aortic Valve Stenosis
        
            
        
    
                
                                    Platelet Adhesion in the Pathobiology of Aortic Stenosis
                                
            
            
        Recruiting
                            
            
                Aortic stenosis (AS) is a serious and common condition that affects 2-3% of the population \>65 years of age in Western countries. It is also responsible for extraordinarily high healthcare expenditures, estimated to be over $6 billion annually,2 in part because the primary treatment for severe AS is aortic valve replacement (AVR) which is resource-intensive. Valve abnormalities are frequently recognized before AS becomes severe, or before there is need for guideline-directed procedural interven...  Read More             
        
        
    Gender:
                ALL
            Ages:
                25 years and above
            Trial Updated:
                04/18/2023
            
            Locations: University of Virginia, Charlottesville, Virginia         
        
        
            Conditions: Aortic Valve Stenosis
        
            
        
    
                
                                    STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)
                                
            
            
        Recruiting
                            
            
                The TVT Registry™ is a benchmarking tool developed to track patient safety and real-world outcomes related to the transcatheter aortic valve replacement (TAVR) procedure. Created by The Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC), the TVT Registry is designed to monitor the safety and efficacy of this new procedure for the treatment of aortic stenosis.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/23/2022
            
            Locations: American College of Cardiology, Washington, District of Columbia         
        
        
            Conditions: Aortic Valve Stenosis
        
            
        
    1 - 12 of 12
            
            
        